Sociedad Americana de Hirudoterapia

Federal Agency for Medicines and Health Products

FAMHP · Belgium · europe

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Belgium's federal agency for medicines and health products — applies EU MDR for devices; leech-specific regulation has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Belgium
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Loi du 15 juin 2022 relative aux dispositifs médicaux (Belgian Medical Devices Act)
  • Regulation (EU) 2017/745 (MDR) — direct effect

Prescriber Requirements

  • Belgian-licensed médecin / arts prescription required
  • Scope of non-conventional practitioners under the Loi Colla (1999) and subsequent royal decrees for hirudotherapy not independently verified by ASH

Supply Chain & GMP

EU MDR-aligned registration with FAMHP; trilingual French / Dutch / German labelling per Belgian language law; cold chain per manufacturer specifications.

Import/Export Rules

Intra-EU free movement. Third-country imports through FAMHP notification, FAVV / AFSCA for live-invertebrate clearance, and standard CITES Appendix II paperwork.

Reimbursement Context

INAMI / RIZIV covers inpatient indications via the Belgian nomenclature; specific hirudotherapy reimbursement status not independently verified by ASH.

ASH Editorial Notes

Belgium recognises four non-conventional medicine modalities under the Loi Colla (acupuncture, chiropractic, homeopathy, osteopathy); hirudotherapy is not on the recognised list. Specific regulatory practice has not been independently verified by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.